Review article
Adjuvant Treatment with Trastuzumab in Patients with Breast Cancer
Dtsch Arztebl 2006; 103(50): A-3406
; ; ; ; ;
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.
| 1. | Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland Hrsg. in Zusammenarbeit mit dem Robert Koch Institut: Krebs in Deutschland. Häufigkeiten und Trends. Saarbrücken 2006, 52. |
| 2. | Goldhirsch A, Glick JH, Gelber RD et al.: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16: 1569–83. MEDLINE |
| 3. | Slamon DJ, Godolphin W, Jones LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989: 244: 707–12. MEDLINE |
| 4. | National Institute for Health and Clinical Excellence (NICE): Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. www.nice.org.uk |
| 5. | Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–84. MEDLINE |
| 6. | Piccart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353; 1659–72. MEDLINE |
| 7. | Smith I, Procter M, Gelber RD et al.: Improved survival with trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. Lancet 2006 angenommen. |
| 8. | Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809–20. MEDLINE |
| 9. | Buzdar AU, Ibrahim NK, Francis D et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 1–10. MEDLINE |
| 10. | Tan-Chiu E, Yothers G, Romond E et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811–9. MEDLINE |
| 11. | Arbeitsgemeinschaft Gynäkologische Onkologie e.V. (AGO) Organkommission Mammakarzinom (2006): Adjuvante Therapie mit Trastuzumab. www.ago-online.org |
